An article published in the Journal of Drugs in Dermatology evaluated twice-daily ruxolitinib cream 1.5% compared to twice-daily 0.1% triamcinolone cream in adults with mild-to-moderate atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results